Literature DB >> 22403237

Childhood pneumonia as a global health priority and the strategic interest of the Bill & Melinda Gates Foundation.

Richard A Adegbola1.   

Abstract

Pneumonia kills more children than any other disease--more than HIV/AIDS, malaria, and measles combined. Introduction of vaccines against pneumococcus and Haemophilus influenzae type b (the most important causes of severe pneumonia in young children), increasing resistance to antibiotics, and changes in HIV prevalence will likely change patterns of pneumonia etiology in developing countries. Studies such as Pneumonia Etiology Research for Child Health (PERCH) that take advantage of new diagnostic technologies are needed to provide an updated and more precise description of the microbial causes of pneumonia and to inform decisions around treatment algorithms and vaccine development and introduction. In recognition of its importance for global health and especially its significance as an ongoing cause of gross inequity in risks, The Bill & Melinda Gates Foundation has made pneumonia an important part of its global health strategy and PERCH a centerpiece of its Pneumonia Program.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22403237     DOI: 10.1093/cid/cir1051

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  Immunization status of children 1-5 years old seen at the Emergency Pediatric Unit of a Teaching Hospital in North-Central Nigeria.

Authors:  Esther S Yiltok; Jonathan C Daboer; Edward M Dachalson; Mathilda E Banwat; Augustine O Ebonyi; Helen O Akhiwu; David D Shwe; Tolulope O Afolaranmi
Journal:  Germs       Date:  2022-03-31

Review 2.  Childhood pneumococcal disease in Africa - A systematic review and meta-analysis of incidence, serotype distribution, and antimicrobial susceptibility.

Authors:  Pui-Ying Iroh Tam; Beth K Thielen; Stephen K Obaro; Ann M Brearley; Alexander M Kaizer; Haitao Chu; Edward N Janoff
Journal:  Vaccine       Date:  2017-03-09       Impact factor: 3.641

3.  Pathogen chip for respiratory tract infections.

Authors:  Eric A F Simões; Champa Patel; Wing-Kin Sung; Charlie W H Lee; Kuan Hon Loh; Marilla Lucero; Hanna Nohynek; Geraldine Nai; Pei Ling Thien; Chee Wee Koh; Yang Sun Chan; Jianmin Ma; Sebastian Maurer-Stroh; Phyllis Carosone-Link; Martin L Hibberd; Christopher W Wong
Journal:  J Clin Microbiol       Date:  2013-01-09       Impact factor: 5.948

4.  Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries.

Authors:  Igor Rudan; Katherine L O'Brien; Harish Nair; Li Liu; Evropi Theodoratou; Shamim Qazi; Ivana Lukšić; Christa L Fischer Walker; Robert E Black; Harry Campbell
Journal:  J Glob Health       Date:  2013-06       Impact factor: 4.413

5.  Understanding the development and perception of global health for more effective student education.

Authors:  Xinguang Chen
Journal:  Yale J Biol Med       Date:  2014-09-03

6.  PERCH in Perspective: What Can It Teach Us About Pneumonia Etiology in Children?

Authors:  Keith P Klugman; Gail L Rodgers
Journal:  Clin Infect Dis       Date:  2017-06-15       Impact factor: 9.079

7.  Antimicrobial Resistance and Molecular Characterization of Staphylococcus aureus Causing Childhood Pneumonia in Shanghai.

Authors:  Zhen Song; Fei-Fei Gu; Xiao-Kui Guo; Yu-Xing Ni; Ping He; Li-Zhong Han
Journal:  Front Microbiol       Date:  2017-03-21       Impact factor: 5.640

8.  Surveillance of respiratory viruses in the outpatient setting in rural coastal Kenya: baseline epidemiological observations.

Authors:  Joyce Uchi Nyiro; Patrick Munywoki; Everlyn Kamau; Charles Agoti; Alex Gichuki; Timothy Etyang; Grieven Otieno; D James Nokes
Journal:  Wellcome Open Res       Date:  2018-07-25

9.  Who is Funding What in the Fight Against Pneumonia?

Authors:  Wei Shen Lim
Journal:  EBioMedicine       Date:  2015-08-18       Impact factor: 8.143

10.  Sequence diversity of NanA manifests in distinct enzyme kinetics and inhibitor susceptibility.

Authors:  Zhongli Xu; Susanne von Grafenstein; Elisabeth Walther; Julian E Fuchs; Klaus R Liedl; Andreas Sauerbrei; Michaela Schmidtke
Journal:  Sci Rep       Date:  2016-04-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.